The Global Gastrointestinal Drugs Market report, which is now available at ReportLinker, is expected to grow at a CAGR (compound annual growth rate) of 3.6% by the end of 2026.
The market is predicted to increase from $71.85 billion in 2021 to $86.96 billion in 2026.
Gastrointestinal drugs are often used for the treatment of constipation, hemorrhoids, irritable bowel syndrome (IBS), ulcerative colitis, diverticular disease, perianal infections, and anal fissures.
The gastrointestinal disease drugs include anti-peptic agents, such as antacids, antagonists, proton pump inhibitors (PPIs), sucralfate, and misoprostol. They also include antiemetics, adsorbents, anticholinergics, intestinal flora modifiers, opiates, emollient/surfactants, simulant/irritant, among others.
Some of the most commonly used GI drugs include antacids, acid-reducers, antiulcerants, antiobesity, antiemetics, and antidiarrhoeals. Antacids reduce the secretion of stomach acid to relieve indigestion and heartburn.
There are various prescription and OTC GI drugs, which are distributed by hospital pharmacies, retail pharmacies, large-chain drug stores, and online pharmacies.
In terms of regional segmentation, North America was the largest region in the market in 2021. By 2026, Middle East is expected to be the fastest growing region. The regions covered in the report are North America, South America, Asia-Pacific, Western Europe, Eastern Europe, Middle East and Africa.
During the forecast period, the growth of the GI drugs market will be restrained by the patent expiration of brand-name drugs. Most companies invest a large sum of money in the drug development process and patents.
Some of the key industry players include Takeda, Bayer AG, Abbott Laboratories, Otsuka, Johnson & Johnson, Reckitt Benckiser, and Bausch Health.
Major companies are investing in developing oral capsules of macromolecular drugs for gastrointestinal diseases, making the drugs more effective. Macromolecular drugs like peptides, proteins, and antibodies form a new class of drugs, which can be useful in treating common GI tract issues, especially IBD.
Typically, macromolecular drugs are injected and just a fraction of the dose reaches the affected sites in the GI tract. Therefore, companies, such as Eli Lilly, have been investing in making oral capsules for macromolecular drugs. It invested $5 million to enter into a collaboration with Entrega to study the oral delivery of macromolecules, such as peptides.
